Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Colonic crypt organization and tumorigenesis.

Humphries A, Wright NA.

Nat Rev Cancer. 2008 Jun;8(6):415-24. doi: 10.1038/nrc2392. Epub 2008 May 15. Review.

PMID:
18480839
2.

Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice.

Alferez D, Wilkinson RW, Watkins J, Poulsom R, Mandir N, Wedge SR, Pyrah IT, Smith NR, Jackson L, Ryan AJ, Goodlad RA.

Mol Cancer Ther. 2008 Mar;7(3):590-8. doi: 10.1158/1535-7163.MCT-07-0433.

3.

The development of duodenal microadenomas in FAP patients: the human correlate of the Min mouse.

Preston SL, Leedham SJ, Oukrif D, Deheregoda M, Goodlad RA, Poulsom R, Alison MR, Wright NA, Novelli M.

J Pathol. 2008 Feb;214(3):294-301.

PMID:
18085615
4.

The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.

Gridelli C, Maione P, Rossi A, De Marinis F.

Oncologist. 2007 Oct;12(10):1183-93. Review.

5.

APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice.

Caldwell CM, Green RA, Kaplan KB.

J Cell Biol. 2007 Sep 24;178(7):1109-20.

6.

Autocrine VEGF signaling is required for vascular homeostasis.

Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML.

Cell. 2007 Aug 24;130(4):691-703.

7.

Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis.

Yamamoto H, Yun EJ, Gerber HP, Ferrara N, Whitsett JA, Vu TH.

Dev Biol. 2007 Aug 1;308(1):44-53. Epub 2007 May 3.

8.

Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.

Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10625-30. Epub 2007 Jun 6.

9.

Bevacizumab in the treatment of non-small-cell lung cancer.

Stinchcombe TE, Socinski MA.

Oncogene. 2007 May 28;26(25):3691-8. Review.

PMID:
17530022
10.

Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.

Ellis LM.

Semin Oncol. 2006 Oct;33(5 Suppl 10):S1-7. Review.

PMID:
17145519
11.

Smad4 signalling in T cells is required for suppression of gastrointestinal cancer.

Kim BG, Li C, Qiao W, Mamura M, Kasprzak B, Anver M, Wolfraim L, Hong S, Mushinski E, Potter M, Kim SJ, Fu XY, Deng C, Letterio JJ.

Nature. 2006 Jun 22;441(7096):1015-9. Erratum in: Nature. 2006 Dec 7;444(7120):780. Kasperczak, Barbara [corrected to Kasprzak, Barbara].

PMID:
16791201
12.

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.

Goodlad RA, Ryan AJ, Wedge SR, Pyrah IT, Alferez D, Poulsom R, Smith NR, Mandir N, Watkins AJ, Wilkinson RW.

Carcinogenesis. 2006 Oct;27(10):2133-9. Epub 2006 Jun 16.

PMID:
16782971
13.

VEGF receptor signalling - in control of vascular function.

Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L.

Nat Rev Mol Cell Biol. 2006 May;7(5):359-71. Review.

PMID:
16633338
14.

VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells.

Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Jung S, Chimenti S, Landsman L, Abramovitch R, Keshet E.

Cell. 2006 Jan 13;124(1):175-89. Erratum in: Cell. 2006 Aug 25;126(4):811. Yung, Steffen [corrected to Jung, Steffen].

15.

Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells.

Yang AD, Camp ER, Fan F, Shen L, Gray MJ, Liu W, Somcio R, Bauer TW, Wu Y, Hicklin DJ, Ellis LM.

Cancer Res. 2006 Jan 1;66(1):46-51.

16.

p16(Ink4a) inhibits histologic progression and angiogenic signaling in min colon tumors.

Gibson SL, Boquoi A, Chen T, Sharpless NE, Brensinger C, Enders GH.

Cancer Biol Ther. 2005 Dec;4(12):1389-94. Epub 2005 Dec 9.

17.

Mutation of smooth muscle myosin causes epithelial invasion and cystic expansion of the zebrafish intestine.

Wallace KN, Dolan AC, Seiler C, Smith EM, Yusuff S, Chaille-Arnold L, Judson B, Sierk R, Yengo C, Sweeney HL, Pack M.

Dev Cell. 2005 May;8(5):717-26.

18.

The epithelial-mesenchymal transition (EMT) and colorectal cancer progression.

Bates RC, Mercurio AM.

Cancer Biol Ther. 2005 Apr;4(4):365-70. Epub 2005 Apr 4. Review.

PMID:
15846061
19.

VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms.

Schoeffner DJ, Matheny SL, Akahane T, Factor V, Berry A, Merlino G, Thorgeirsson UP.

Lab Invest. 2005 May;85(5):608-23.

20.

Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.

Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, Ellis LM.

Oncogene. 2005 Apr 14;24(16):2647-53.

PMID:
15735759

Supplemental Content

Support Center